The Swiss company SIGVARIS, 100% family-owned since it was founded, is the global market leader in the manufacture of medical compression garments and celebrated its 150th anniversary in 2014. The company was established in 1864 in Winterthur. For about 100 years, SIGVARIS produced “rubber-elastic textiles”, which it sold both in Switzerland and abroad.
From 1958 to 1960, the company collaborated with Dr. Karl Sigg and developed a medical compression stocking to improve venous function and relieve venous-related conditions. The product portfolio was expanded in 2009 when the WELL BEING and SPORTS lines were added to the main MEDICAL line. WELL BEING stockings have a preventive function and relieve the early symptoms of leg conditions. SPORTS products improve athlete performance and recovery time.
The company can look back at a successful track record as it moves continuously towards the future, in keeping with its motto “Every day a step further”. Customers around the world include pharmacies, chemists, orthopaedic and medical specialist stores as well as doctors and hospitals. The Group produced about 8 million pairs of stockings in 2014 and generated revenue of around CHF 250 million.
SIGVARIS Group
The Swiss Group SIGVARIS has its headquarters in Switzerland and is the global market leader in the manufacture of medical compression garments. It employs about 1,400 people and has its own production plants in Switzerland, France, the US and Brazil. SIGVARIS is close to its customers, having subsidiaries in Germany, Austria, England, Italy, Canada, China, Australia and the United Arab Emirates as well as distributors in more than 70 countries on all continents. The Group pursues an international growth strategy on the solid foundation of 150 years of success.
Contact
Rue Barthélémy Thimonnier, 42170 Saint-Just-Saint-Rambert, France
+33 4 77 36 08 90
As president of the French League Against Cancer, Dr Daniel Nizri highlights the organization’s 106-year legacy of fighting cancer through research funding, health promotion, patient support, and advocacy. He discusses…
After offloading its consumer healthcare division in 2022 and in view of the gradual erosion of its top seller, Somatuline, Ipsen opted to aggressively seek external assets to enrich its…
France is the third most significant clinical research destination in Europe, participating in 50 percent of the trials initiated across the continent. While favourable government policies and unique strengths such…
Hubert Mechin, president of AFCROs, the association that groups clinical research organisations in France, details the organisation’s efforts to help its members stay abreast of changes in the European regulatory…
With revenues projected to reach USD 27.01 billion in 2024, France’s pharma market is ranked fifth globally. Home to a number of well-established local pharma players and a sought-after destination…
Just five months after taking office, Aurélien Rousseau resigned from his role as health minister in protest against France’s recently adopted immigration law. Interim replacement Agnès Firmin Le Bodo, the…
France’s life sciences industry is falling behind its European neighbours, its growth deeply hampered, the French life sciences think tank G5 Santé claims, by abusive paybacks. While the government has…
The latest news from French healthcare and pharma, including an update on the hospital crisis; MaaT Pharma and Skyepharma’s new cGMP microbiome facility; Sanofi’s offloading of central nervous system drugs…
In the French government’s recent cabinet reshuffle, prime minister Elisabeth Borne’s former chief of staff, Aurélien Rousseau was appointed as the new minister of health. Rousseau, having piloted the Île-de-France…
The Contract Development and Manufacturing Organization (CDMO) sector has flousished in recent years as Big Pharma has shifted its attention to its core R&D activities and outsourced other supply chain…
Despite an uncertain macro-economic environment, the French health technology sector continues its growth trajectory, demonstrating both entrepreneurial dynamism and maturity, according to the new edition of the France Biotech study…
The latest news from French pharma, including fears of medicine shortages and suspension of online sales of paracetamol, CARMAT’s artificial heart product entering a study in France, Sanofi’s expanded deal…
See our Cookie Privacy Policy Here
